Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit is substantial in the second-line treatment of ALK+ advanced non-small cell lung cancer (NSCLC). |
Clinical Added Value
| moderate |
XALKORI provides a moderate improvement in actual benefit (level III) in the treatment strategy of ALK+ advanced non-small cell lung cancer as a second-line therapy and compared with docetaxel or pemetrexed. |
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
z1XDDn9pKCA6vqx7
